Perspectives on Repurposed Drugs Based on Globally Accepted Therapeutic Guidelines to Combat SARS-CoV-2 Infection

References

• Palacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M. COVID-19, a worldwide public health emergency. Rev Clin Esp (Barc). 2020. Available from: www.ncbi.nlm.nih.gov/pmc/articles/PMC7173827/. Accessed May 3, 2020.
   Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). COVID-19, MERS & SARS [Internet]. National Institute of Health (NIH);2020. Available from: www.niaid.nih.gov/diseases-conditions/covid-19. Accessed May 8, 2020.
   Google Scholar
• Lehrer S, Rheinstein PH. Human gene sequences in SARS-CoV-2 and other viruses. In Vivo (Brooklyn). 2020;34(3Suppl):1633–1636. doi:10.21873/invivo.11954
   Web of Science ®Google Scholar
• Coronavirus Disease (COVID-19) - events as they happen [Internet]. World Health Organization (WHO). 2020. Available from: www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. Accessed May 12, 2020.
   Google Scholar
• Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157–160.
   PubMedGoogle Scholar
• Khan S, Siddique R, Ali A, Xue M, Nabi G. Novel coronavirus, poor quarantine, and the risk of pandemic. J Hosp Infect. 2020;104(4):449–450. doi:10.1016/j.jhin.2020.02.002
   PubMed Web of Science ®Google Scholar
• Coronavirus Disease 2019 (COVID-19) [Internet]. Centers for Disease Control and Prevention (CDC). 2020. Available from: www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html. Accessed May 18, 2020.
   Google Scholar
• Coronavirus Disease (COVID-19) Situation Reports [Internet]. World Health Organization (WHO). 2020. Available from: www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed May 20, 2020.
   Google Scholar
• COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health (NIH); 2020. Available from: www.covid19treatmentguidelines.nih.gov/. Accessed May 21, 2020.
   Google Scholar
• Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–582. doi:10.7326/M20-0504
   PubMed Web of Science ®Google Scholar
• Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley D, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi:10.1016/S0140-6736(20)30628-0
   PubMed Web of Science ®Google Scholar
• Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. doi:10.1016/j.ijantimicag.2020.105954
   PubMed Web of Science ®Google Scholar
• Jose R, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–e47. doi:10.1016/S2213-2600(20)30216-2
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
   PubMed Web of Science ®Google Scholar
• Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847. doi:10.1111/jth.14768
   PubMed Web of Science ®Google Scholar
• Ingraham NE, Lotfi-Emran S, Thielen BK, et al. Immunomodulation in COVID-19. Lancet Respir Med. 2020;8(6):544–546. doi:10.1016/S2213-2600(20)30226-5
   Web of Science ®Google Scholar
• Vincent J, Taccone F. Understanding pathways to death in patients with COVID-19. Lancet Respir Med. 2020;8(5):430–432. doi:10.1016/S2213-2600(20)30165-X
   PubMed Web of Science ®Google Scholar
• Clinical management of COVID-19: interim guidance [Internet]. World Health Organization (WHO). 2020. Available from: www.who.int/publications/i/item/clinical-management-of-covid-19. Accessed June 8, 2020.
   Google Scholar
• Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. doi:10.1016/j.thromres.2020.04.013
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–10975. doi:10.1073/pnas.2005615117
   PubMed Web of Science ®Google Scholar
• Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis. 2014;20:42–46. doi:10.1016/j.ijid.2013.12.003
   PubMed Web of Science ®Google Scholar
• Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study. Clin Infect Dis. 2020;70(9):1837–1844.
   PubMed Web of Science ®Google Scholar
• Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256. doi:10.1136/thorax.2003.012658
   PubMed Web of Science ®Google Scholar
• Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090–1095. doi:10.1016/S1473-3099(14)70920-X
   PubMed Web of Science ®Google Scholar
• Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN- alfa2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother. 2015;70(7):2129–2132. doi:10.1093/jac/dkv085
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–1252. doi:10.1056/NEJMoa1507247
   PubMed Web of Science ®Google Scholar
• Smolen JS, Genovese MC, Takeuchi T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol. 2019;46(1):7–18. doi:10.3899/jrheum.171361
   PubMed Web of Science ®Google Scholar
• Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857. doi:10.1001/jamanetworkopen.2020.8857
   PubMed Web of Science ®Google Scholar
• Chen J, Lui D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. J Zhejiang Univ. 2020;49(2):215–219.
   Google Scholar
• Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an Open-Label Control Study. Engineering (Beijing). 2020. doi:10.1016/j.eng.2020.03.007
   Google Scholar
• “Solidarity” clinical trial for COVID-19 treatments [Internet]. World Health Organization (WHO). 2020. Available from: www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. Accessed July 13, 2020.
   Google Scholar
• Institut National de la Santé Et de la Recherche Médicale, France. Trial of treatments for COVID-19 in hospitalized adults (DisCoVeRy). Clinicaltrials.gov. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04315948. Accessed July 13, 2020.
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826. doi:10.1056/NEJMoa2007764
   PubMed Web of Science ®Google Scholar
• Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428‐430. doi:10.1016/S2468-1253(20)30057-1
   Web of Science ®Google Scholar
• Chau TN, Lee KC, Yao H. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004;39(2):302–310. doi:10.1002/hep.20111
   PubMed Web of Science ®Google Scholar
• Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement [Internet]. Alexandria, Virginia, USA: American Association for the Study of Liver Diseases (AASLD);2020. Available from: www.aasld.org/sites/default/files/2020-06/AASLD-COVID19-ExpertPanelConsensusStatement-June252020-v2-FINAL.pdf. Accessed June 28, 2020.
   Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454. doi:10.1038/nature02145
   PubMed Web of Science ®Google Scholar
• Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113. doi:10.1016/j.jhepr.2020.100113
   PubMedGoogle Scholar
• Consensus Statement for Patients with Genetic Heart Disease and COVID-19 [Internet]. Sydney, New South Wales, Australia: Cardiac Society of Australia and New Zealand (CSANZ);2020. Available from: www.csanz.edu.au/wp-content/uploads/2020/04/CSANZ-Consensus-statement-for-patients-with-Genetic-Heart-Disease-and-COVID-19-web.pdf. Accessed July 1, 2020.
   Google Scholar
• Rico-Mesa JS, White A, Anderson AS. Outcomes in patients with COVID-19 infection taking ACEI/ARB. Curr Cardiol Rep. 2020;22(5):31. doi:10.1007/s11886-020-01291-4
   PubMed Web of Science ®Google Scholar
• Sommerstein R, Kochen M, Messerli F, Gräni C. Coronavirus disease 2019 (COVID‐19): do angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? J Am Heart Assoc. 2020;9(7). doi:10.1161/JAHA.120.016509
   Web of Science ®Google Scholar
• South A, Brady T, Flynn J. ACE2 (angiotensin-converting enzyme 2), COVID-19, and ACE inhibitor and Ang II (Angiotensin II) receptor blocker use during the pandemic. Hypertension. 2020;76(1):16–22. doi:10.1161/HYPERTENSIONAHA.120.15291
   PubMed Web of Science ®Google Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8
   PubMed Web of Science ®Google Scholar
• Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75(6):1382–1385. doi:10.1161/HYPERTENSIONAHA.120.15082
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671–1681. doi:10.1161/CIRCRESAHA.120.317134
   PubMed Web of Science ®Google Scholar
• Mikuls T, Johnson S, Fraenkel L, et al. American college of rheumatology guidance for the management of rheumatic disease in adult patients during the COVID‐19 pandemic: version 1. Arthritis Rheumatol. 2020;72(9):1–11.
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA‐EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–1782. doi:10.1136/annrheumdis-2012-201940
   PubMed Web of Science ®Google Scholar
• Duran‐Barragan S, McGwin G Jr, Vila LM, Reveille JD, Alarcon GS. Angiotensin converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus–results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford). 2008;47:1093–1096. doi:10.1093/rheumatology/ken208
   PubMed Web of Science ®Google Scholar
• Tselios K, Gladman DD, Su J, Urowitz MB. Does Renin-angiotensin system blockade protect lupus nephritis patients from atherosclerotic cardiovascular events? A Case-Control Study. Arthritis Care Res (Hoboken). 2016;68(10):1497–1504. doi:10.1002/acr.22857
   Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. COVID‐19 rapid guideline: managing symptoms (including at the end of life) in the community. 2020. Available from: www.nice.org.uk/guidance/ng163. Accessed July 7, 2020.
   Google Scholar
• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934. doi:10.1001/jamainternmed.2020.0994
   PubMed Web of Science ®Google Scholar
• D’Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transplant. 2020;26(6):832–834. doi:10.1002/lt.25756
   PubMed Web of Science ®Google Scholar
• RECOVERY (Randomized Evaluation of COVID-19 Therapy) trial and University of Oxford. Low-cost dexamethasone reduces death by up to one third in hospitalized patients with severe respiratory complications of COVID-19 [Internet]. 2020. Available from: https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf. Accessed July 9, 2020.
   Google Scholar
• Ibrahim A, Ahmed M, Conway R, Carey J. Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis. J Clin Med. 2018;8(1):15. doi:10.3390/jcm8010015
   PubMed Web of Science ®Google Scholar
• Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology. 2007;46(7):1157–1160. doi:10.1093/rheumatology/kem076
   PubMed Web of Science ®Google Scholar
• COVID-19 Rapid Guideline: Chronic Kidney Disease (CKD) - [NICE Guideline NG176] [Internet]. London, United Kingdom:National Institute for Health and Care Excellence (NICE);May 15, 2020. Available from: https://www.nice.org.uk/guidance/ng176/resources/covid19-rapid-guideline-chronic-kidney-disease-pdf-66141964574917. Accessed July 12, 2020.
   Google Scholar
• Guidance for Clinicians with Patients Receiving Immunosuppression Treatment for Autoimmune Conditions of Their Native Kidneys During Covid-19 [Internet]. Version 2. Bristol, United Kingdom:The Renal Association;April 1, 2020. Available from: https://renal.org/wp-content/uploads/2020/04/Treatment-of-patients-with-AI-kidney-disease-during-Covid19-outbreak-010420.pdf. Accessed July 13, 2020.
   Google Scholar
• National Institute for Health and Care Excellence. COVID 19 rapid guideline: renal transplantation. June 19, 2020. Available from: www.nice.org.uk/guidance/ng178. Accessed July 13, 2020.
   Google Scholar
• Bornstein S, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546–550. doi:10.1016/S2213-8587(20)30152-2
   PubMed Web of Science ®Google Scholar
• Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020;395(10231):1225–1228. doi:10.1016/S0140-6736(20)30627-9
   PubMed Web of Science ®Google Scholar
• Bramante C, Ingraham N, Murray T, et al. Observational Study of metformin and risk of mortality in patients hospitalized with covid-19. medRxiv. 2020;2020.06.19.20135095.
   Google Scholar
• Liu L, Feng J, Zhang G, et al. Visceral adipose tissue is more strongly associated with insulin resistance than subcutaneous adipose tissue in Chinese subjects with pre-diabetes. Curr Med Res Opin. 2018;34(1):123–129. doi:10.1080/03007995.2017.1364226
   PubMed Web of Science ®Google Scholar
• Luo P, Qiu L, Liu Y, et al. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am J Trop Med Hyg. 2020;103(1):69–72. doi:10.4269/ajtmh.20-0375
   PubMed Web of Science ®Google Scholar
• Gupta-Ganguli M, Cox K, Means B, Gerling I, Solomon SS. Does therapy with anti–TNF-α improve glucose tolerance and control in patients with type 2 diabetes? Diabetes Care. 2011;34(7):e121. doi:10.2337/dc10-1334
   PubMedGoogle Scholar
• Blüher M, Fasshauer M, Tönjes A, Kratzsch J, Schön MR, Paschke R. Association of interleukin- 6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes. 2005;113(9):534–537. doi:10.1055/s-2005-872851
   PubMed Web of Science ®Google Scholar
• El-Arabey AA, Abdalla M. Metformin and COVID-19: a novel deal of an old drug [published online ahead of print, 2020 Apr 29]. J Med Virol. 2020. doi:10.1002/jmv.25958
   Web of Science ®Google Scholar
• Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID- 19 mortality. Obesity (Silver Spring). 2020;28:1005.
   PubMed Web of Science ®Google Scholar
• Cameron AR, Morrison VL, Levin D, et al. Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res. 2016;119(5):652–665. doi:10.1161/CIRCRESAHA.116.308445
   PubMed Web of Science ®Google Scholar
• El-Arabey AA. Update on off label use of metformin for obesity. Prim Care Diabetes. 2018;12(3):284–285. doi:10.1016/j.pcd.2018.02.004
   Web of Science ®Google Scholar
• Eric M, Antonio A. Association of metformin and mortality for patients with diabetes who are hospitalized with pneumonia. Eur Res J. 2018;52(Suppl. 62):PA2639.
   Google Scholar
• Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020;80(6):e14–e18. doi:10.1016/j.jinf.2020.03.005
   PubMed Web of Science ®Google Scholar
• Chen Y, Gu F, Guan J-L. Metformin might inhibit virus through increasing insulin sensitivity. Chin Med J (Engl). 2018;131(3):376–377. doi:10.4103/0366-6999.223856
   Web of Science ®Google Scholar